Allogene Therapeutics ALLO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's EPS (diluted)?
- Allogene Therapeutics (ALLO) reported EPS (diluted) of -$0.18 in Q1 2026.
- How has Allogene Therapeutics's EPS (diluted) changed year-over-year?
- Allogene Therapeutics's EPS (diluted) increased by 35.7% year-over-year, from -$0.28 to -$0.18.
- What is the long-term trend for Allogene Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Allogene Therapeutics's EPS (diluted) has grown at a -10.4% compound annual growth rate (CAGR), from -$1.35 to -$0.87.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.